Just a question for the board. I know alot of bigger medical device companies are trying to get their beak wet in molecular diagnostics. What kind of buyout price could we expect with current state of the company along with next generation analyzer?
strong buyout valuations are only achieved on flawless execution or if the sum of the parts valuation signals a huge bargain opportunity. Given the recent setback and the current tiny overall revenue size I wouldn't expect any offer to be put on the table for now. Company will have to prove first that 50% revenue growth rates remain achievable going forward. Would also look for a secondary offering as cash is running low.